MedInCell Stock Rises 2.44% to €26.86, Marking +73% Over One Year Ahead of R&D Day
The Montpellier-based biotech's stock picks up pace mid-session, on the eve of a highly anticipated meeting with analysts. At €26.86, the stock is up 2.44% while the SBF 120 index is down 0.80% at midday. The stock ranks 6th in terms of gains in the index, indicating a performance that goes against the general trend of the Paris market.
An R&D Day Scheduled for Tomorrow, Following a Bullish Trend
MedInCell is hosting its R&D Day live on May 12, 2026. The event follows a favorable stock market sequence: the stock has gained 8.83% over the week and 73.18% over the year. Today's movement continues the breakthrough of a technical resistance that occurred on May 6 at €26.14. The price is now in uncharted territory in the short term, above the resistance zone provided at €26.52. The next financial milestone after the R&D Day is the 2026 general assembly, scheduled for September 10.
The Stock Breaks Through the Upper Bollinger Bands
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €26.86, the stock is above the upper Bollinger Band set at €26.51, which is 109% of the band, signaling potential overbuying. The RSI at 62 remains in a non-extreme zone despite the rise, leaving room before the typical overheating zone of 70. The three moving averages are aligned below the price: MM20 at €24.48 (a gap of +9.72%), MM50 at €23.04, and MM200 at €24.43. The configuration confirms the bullish orientation established since April, during which the stock moved from approximately €22.80 to over €26. The next concrete appointment for shareholders is the R&D Day on May 12, 2026.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
